- Login
- Manage Portfolio
- Post a StockTalk
- Write an Instablog
- Get Daily Email Alert
-
Seeking Alpha
|
|
| 52wk high: | |
| 52wk low: | |
| EPS: | |
| PE: | |
| Dividend: | |
| Yield: | |
| Market Cap: | |
| Exchange: | |
-
15 Possible Healthcare Breakout Stocks
-
Aradigm: Hard to Value, But Significant Upside
-
Bio Medical Stock Sector is Where the Action Is
-
Emisphere: Improving Drug Delivery
-
FDA and Clinical Trial Updates: United Therapeutics Faces Delays
-
Pharmas and Biotech: Vying for Outsize Insulin Profits
-
Biotech Outlook: M&A Will Continue
-
BioMarin, Myriad, and Regeneron Show a Quiet Strength
-
Mannkind: Overlooked Biotech With Excellent Prospects (Part VI)
-
Mannkind: Overlooked Biotech With Excellent Prospects (Part V)
-
Mannkind: Overlooked Biotech With Excellent Prospects (Part IV)
-
Mannkind: Overlooked Biotech With Excellent Prospects (Part III)
-
Mannkind: Overlooked Biotech With Excellent Prospects (Part II)
-
ADA's 68th Scientific Sessions: A New Look at Insulin Therapy
-
Mannkind: Overlooked Biotech With Excellent Prospects (Part I)
-
Biotech Sector Continues to Outperform
-
Generex Biotech's Oral-lyn Granted Special Access Authorization by Health Canada
-
Fixing Pfizer
-
Generex Biotech: A Breath of Fresh Insulin
-
Oral Insulin: Balancing Safety with Efficacy
-
MannKind: No Partnership Likely for Inhalable Insulin
-
Mannkind Slammed: No Guarantees in Drug Safety
-
Generex Biotechnology: Oral-lyn Buccal Insulin Takes Center Stage
-
Nektar, Mannkind Suffer from Pfizer's (Discontinued) Inhaled Insulin Effects
-
Inhaled Insulin: One Giant Leap for MannKind
-
Inhaled Insulin: Eli Lilly On Its 'Last Breath'?
-
Alkermes, Lilly, Mannkind: Inhaled Insulin Just Got Interesting
-
Eat It, Breathe It, Soak in It? Drug Administration Gets Tricky
-
Monday's Under The Radar News
-
5 Stocks with Atmospheric Price Sales Ratios
-
Analyst Upgrades & Downgrades for Friday, July 21, 2006